Form 4: Vanda Pharmaceuticals Executive Receives RSU Grant

Daniel Patrick McGuire, SVP, GC and Secretary of Vanda Pharmaceuticals, was granted 80,000 restricted stock units.

Summary

• Daniel Patrick McGuire, SVP, General Counsel, and Secretary of Vanda Pharmaceuticals Inc. (VNDA), received an award of 80,000 restricted stock units (RSUs).
• The grant was issued on June 4, 2026.
• The RSUs vest in four equal annual installments, beginning June 4, 2027, contingent upon continued employment.
• Following this transaction, the reporting person's total beneficial ownership of common stock is 109,982 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via a four-year vesting schedule.

Negatives

• Potential future dilution for existing shareholders upon the vesting and settlement of the RSU awards.

Risks

• Vesting is subject to the reporting person remaining continuously employed by the issuer through each annual vesting date.

Future Outlook

The RSU award vests in four equal annual installments starting June 4, 2027, provided the reporting person remains employed by the company.

Industry Context

StockSavvy.ai notes that equity grants to key executives are standard practice in the biopharmaceutical industry to ensure leadership retention and align management incentives with long-term corporate performance.

Comparison to Industry Standards

• The use of four-year vesting schedules for RSU grants is consistent with standard corporate governance and compensation practices for mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual settlement of the RSU awards.

Next Steps

• Vesting of the first 20,000 RSUs on June 4, 2027, subject to continued employment.

Key Dates

Keywords

Vanda Pharmaceuticals, VNDA, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation